Liang Liu

List of Publications by Year
in descending order

18 papers	3,162 citations	759233 12 h-index	839539 18 g-index
18 all docs	18 docs citations	18 times ranked	5274 citing authors

#	Article	IF	Citations
1	Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. Cancer Cell, 2014, 25, 501-515.	16.8	1,198
2	Breast-cancer-secreted miR-122 reprograms glucoseÂmetabolism in premetastatic niche toÂpromoteÂmetastasis. Nature Cell Biology, 2015, 17, 183-194.	10.3	895
3	Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nature Cell Biology, 2018, 20, 597-609.	10.3	306
4	Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-ÎºB. Scientific Reports, 2014, 4, 5750.	3.3	270
5	Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting ONECUT2. Cancer Research, 2019, 79, 3608-3621.	0.9	129
6	Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. Frontiers in Immunology, 2017, 8, 404.	4.8	73
7	TGFÎ² Induces â€œBRCAnessâ€•and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes. Molecular Cancer Research, 2014, 12, 1597-1609.	3.4	56
8	Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death and Differentiation, 2018, 25, 1160-1173.	11.2	51
9	The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancerâ€”A Phase II Study. Frontiers in Immunology, 2021, 12, 772450.	4.8	42
10	Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clinical Cancer Research, 2018, 24, 2370-2382.	7.0	39
11	Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). Annals of Translational Medicine, 2022, 10, 229-229.	1.7	25
12	Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). Frontiers in Oncology, 2022, 12, 831345.	2.8	18
13	CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. Cell Death and Disease, 2022, 13, 441.	6.3	18
14	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death and Disease, 2019, 10, 475.	6.3	16
15	Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway. Molecular Immunology, 2017, 81, 102-107.	2.2	11
16	Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357. Signal Transduction and Targeted Therapy, 2020, 5, 244.	17.1	10
17	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. Frontiers in Immunology, 2021, 12, 779248.	4.8	3
18	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. Cancer Biology and Medicine, 2021, 18, 0-0.	3.0	2